Shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $2.32.
Separately, StockNews.com initiated coverage on Cara Therapeutics in a research report on Sunday. They set a “sell” rating on the stock.
Read Our Latest Analysis on Cara Therapeutics
Cara Therapeutics Price Performance
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. The company had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.26 million. On average, research analysts expect that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cara Therapeutics stock. Marquette Asset Management LLC bought a new position in Cara Therapeutics, Inc. (NASDAQ:CARA – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned about 0.17% of Cara Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 44.66% of the company’s stock.
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Featured Stories
- Five stocks we like better than Cara Therapeutics
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Is Spotify Stock Poised to Soar? Options Traders Think So
- Why Invest in 5G? How to Invest in 5G Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.